What is the ARX517 fast track designation?
•
4 min read
In July 2023, the U.S. Food and Drug Administration (FDA) granted Ambrx's ARX517 **fast track designation** for metastatic castration-resistant prostate cancer (mCRPC) that has progressed on prior therapy. This status is designed to accelerate the development and review of therapies for serious conditions with unmet medical needs, bringing promising treatments to patients more rapidly.
